Compare HII & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HII | MEDP |
|---|---|---|
| Founded | 1886 | 1992 |
| Country | United States | United States |
| Employees | 44000 | N/A |
| Industry | Marine Transportation | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.4B | 16.1B |
| IPO Year | 2010 | 2016 |
| Metric | HII | MEDP |
|---|---|---|
| Price | $435.71 | $452.61 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 12 |
| Target Price | $379.50 | ★ $496.09 |
| AVG Volume (30 Days) | ★ 558.7K | 396.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | 10.24 | ★ 20.98 |
| EPS | ★ 15.39 | 15.28 |
| Revenue | ★ $12,484,000,000.00 | N/A |
| Revenue This Year | $3.14 | $13.07 |
| Revenue Next Year | $5.93 | $7.44 |
| P/E Ratio | ★ $28.71 | $29.26 |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $167.70 | $250.05 |
| 52 Week High | $442.48 | $628.92 |
| Indicator | HII | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 62.43 | 28.80 |
| Support Level | $382.01 | $425.80 |
| Resistance Level | $443.32 | $448.23 |
| Average True Range (ATR) | 18.15 | 25.62 |
| MACD | 1.23 | -8.19 |
| Stochastic Oscillator | 95.72 | 27.40 |
Huntington Ingalls Industries is the largest independent military shipbuilder in the US, spun out from Northrop Grumman in 2011. It operates three segments, two of which are storied shipyards: Ingalls produces non-nuclear-powered ships including amphibious landing ships and Arleigh Burke-class destroyers, while Newport News produces nuclear-powered ships as the only producer of Gerald Ford-class aircraft carriers and a major subcontractor on Virginia- and Columbia-class nuclear submarines. HII shares production of destroyers and nuclear submarines with General Dynamics' Bath Iron Works and Electric Boat shipyards, respectively. The company's mission technologies segment produces uncrewed sea vessels and provides a range of IT and other services to US government agencies.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.